Benzosceptrin C 产品活性：Benzosceptrin C 是一种程序性细胞死亡配体 (PD-L1) 抑制剂，可促进 PD-L1 在通过溶酶体途径降解，增强 T 细胞的细胞毒性并表现出抗肿瘤活性。 产品来源： https://www.medchemexpress.cn/benzosceptrin-c.html 研究领域：Immunology/Inflammation | Apoptosis 作用靶点：PD-1/PD-L1 | Apoptosis 结构分类：生物碱 | 吡咯类生物碱 | 结构分类 In Vitro: Benzosceptrin C (0-10 μM) inhibits PD-L1 expression in CRC cancer cells, enhances T-cell cytotoxicity through PD-L1 checkpoints disruption, and inhibits proliferations of CRC cancer cells RKO and HCT116. Benzosceptrin C (0-10 μM) blocks the palmitoylation of PD-L1 by inhibiting DHHC3, thus promotes the lysosomal degradation of PD-L1, blocks the direct interaction of PD-L1 and PD-1 and exert an immune antitumor effect. In Vivo: Benzosceptrin C (5-50 mg/kg/day, i.p. for 16 days) inhibits tumor growth in MC38 xenograft C57BL/6 mice through activation of tumor-infiltrating T cells and induction of apoptosis. 相关产品：MG-132 | Doxorubicin hydrochloride | Bafilomycin A1 | Tamoxifen | Y-27632 | LY294002 | Paclitaxel | Z-VAD-FMK | Acetylcysteine | Angiotensin II human | 2-Deoxy-D-glucose | Staurosporine | Actinomycin D | SB-431542 | 5-Fluorouracil | Bortezomib | Deferoxamine mesylate | Oxaliplatin | Trametinib | Sorafenib | Temozolomide | Gemcitabine | Decitabine | Mdivi-1 | Rotenone | Etoposide | Elesclomol | Ruxolitinib | Monomethyl auristatin E | DAPT 品牌介绍: MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供最新最全的高品质小分子活性化合物；10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；设有专业的实验中心和严格的质控、验证体系；提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；产品的生物活性多经各国客户实验验证；Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果；专业团队跟踪最新的制药及生命科学研究进展，为您提供全球最新的活性化合物；与世界各大制药公司及知名科研机构建立了长期的合作。